The biotech industry is heavily regulated by the federal government and its science watchdog, the Food and Drug Administration (FDA). As a consequence, biotech investors often evaluate a possible investment by looking at the company's pipeline of future assets. Research and development is a key factor in this sector.
So what biotech companies have the most exciting future prospects? Three Fool.com healthcare contributors like Vertex Pharmaceuticals (VRTX 1.88%), Repligen (RGEN 4.51%), and Recursion Pharmaceuticals (RXRX 9.43%). Here's why they believe these three stocks are the future of biotechnology.
George Budwell (Vertex Pharmaceuticals): Vertex Pharmaceuticals has become a cash-printing machine recently thanks to its groundbreaking cystic fibrosis treatments like Trikafta. This single drug generated a whopping $5.7 billion in sales in 2021.
The company has been using the proceeds from its mega-blockbuster cystic fibrosis franchise to expand into cutting-edge treatment modalities such as stem cell therapy and gene editing. For example, Vertex dipped into its cash reserves in the recent past to buy the privately held biotechs Semma Therapeutics and ViaCyte. These complementary transactions have suddenly made Vertex a potential juggernaut in the world of diabetes care.
The 2019 Semma Therapeutics deal gave the biotech the allogeneic stem-cell product VX-880, aimed at curing type 1 diabetes. And earlier this year, Vertex bought ViaCyte for its cell replacement therapy platform, which is also initially aimed at curing type 1 diabetes.
This ViaCyte transaction also stands out because the biotech has an ongoing collaboration with Vertex's blood disease collaborator, CRISPR Therapeutics. This ViaCyte/CRISPR partnership centers around the development of genetically modified beta cells for the treatment of both type 1 and type 2 diabetes. CRISPR and ViaCyte are reportedly on track to release top-line data from an early-stage trial in type 1 diabetes next year. Human trials for the duo's type 2 therapy could kick off in either late 2023 or early 2024.
In sum, Vertex's cell- and gene-editing-based diabetes care therapies have the potential to bend the curve in terms of the standard of care for this worldwide epidemic. Wall Street, however, doesn't appear to have taken notice of this deep value proposition -- at least not yet. Vertex's stock, after all, seems to be being valued mainly for its cystic fibrosis franchise and pipeline assets in various blood disorders.
Patrick Bafuma (Repligen): When it comes to the future, Repligen is creating the tools that make it all possible. From cell and gene therapy to cutting-edge mRNA vaccines to monoclonal antibody treatment, Repligen is there. This biotech provides the equipment and associated consumables needed for various steps in the manufacturing of today's most complex treatments.
And in a year marred by supply chain and geopolitical issues, Repligen has seemingly been insulated. There was hardly a mention of either of these issues in the last few earnings conference calls. Not bad considering its sales are spread throughout the globe with Europe, North America, and Asia representing 35%, 45%, and 20% of second-quarter revenue, respectively. Despite sales slowing down for COVID-19 treatments and vaccines that Repligen helps manufacture, the company's base business in Q2 was up 41% year over year. The record quarterly revenue of $207.6 million -- up 32% year over year on a constant currency basis -- is a welcome sight for biotech investors in 2022's uncertain market.
If you believe cell and gene therapy are the future of healthcare, then Repligen deserves a second look. The bioprocessing company's cell and gene therapy segment is seeing accelerated growth. Revenue from this business line increased 40% in full year 2021, and growth in Q2 2022 was up almost 70% from the same period a year ago. This puts Repligen on track to smash its own 40% growth target for the division for 2022. There are other signs the future is bright, too. At the end of 2020, there were over 1,200 clinical trials underway worldwide in the cell and gene therapy segment, according to the company. Then there are the FDA estimates for annual revenue growth of over 25% for the entirety of said market through 2025. Put it all together, and Repligen is well positioned to thrive as the backbone of the industry.
Taylor Carmichael (Recursion Pharmaceuticals): Vertex and Repligen are great picks. Both companies are already highly profitable, so the future prospects are grounded in what these companies have already accomplished. Recursion is a different animal. The company doesn't have profits yet, and revenue is still small. But I've opened up a small position here because the upside is so high. If this company has any success, it will dramatically transform drug discovery.
Here's the current paradigm for finding a new drug candidate. You notice a problem in the world of healthcare. You read academic articles to see what has been tried and what has not been tried. You formulate your own hypothesis. And then you collect data by testing your hypothesis in animals, and then in people. That's the basic model for drug discovery -- and it has a spectacular failure rate of over 90%.
Recursion is using supercomputers and artificial intelligence (AI) to create maps of biology. The company's software has already generated 16 petabytes of biological and chemical data. One petabyte equals 1.5 million CD-ROM discs. It's estimated the human brain can store 2.5 petabytes of memory data. So Recursion's AI solution now has more data than six human brains.
Even more importantly, the company's AI solution is running experiments with this data all the time. Recursion's computers have now made 2.4 trillion predictions about biological and chemical relationships. Research scientists can search all this data to create a more informed hypothesis. This is a fundamentally superior model, in my opinion. First you collect and analyze the scientific data, and then you form the hypothesis.
The company has major partners inBayerand Roche. And Recursion has quickly found drug candidates. In the first quarter, the company initiated a phase 2 study for a drug to treat cerebral cavernous malformation. In Q2, the company started a phase 2 study for a molecule to treat neurofibromatosis type 2. This quarter the company will initiate yet another phase 2 study, in a drug treating familial adenomatous polyposis (FAP).
Of course improving the odds does not mean that these drugs are sure things. But I definitely think Recursion is on the right track, and the future of drug discovery will follow this model. So I've made a small investment here while it's early and the company is still small. (Its market cap is under $2 billion.) If I'm right, Recursion will be a foundational holding for biotech investors for many years to come.
Read this article:
These 3 Stocks Are the Future of Biotechnology - The Motley Fool
- Is Weakness In Bloomage BioTechnology Corporation Limited (SHSE:688363) Stock A Sign That The Market Could be ... - Simply Wall St - March 28th, 2024
- Insiders were the biggest winners as Beijing Bohui Innovation Biotechnology Group Co., Ltd.'s (SZSE:300318) market ... - Simply Wall St - March 28th, 2024
- Biotechnology CEO and inventor of SiriusXM Satellite Radio Martine Rothblatt to deliver graduation address to the ... - EurekAlert - March 28th, 2024
- 6 biotechnology universities in the UK leading the way for future talent - Labiotech.eu - March 28th, 2024
- Is Vera Therapeutics Inc (VERA) a Bad Choice in Biotechnology Wednesday? - InvestorsObserver - March 28th, 2024
- Is G1 Therapeutics Inc (GTHX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- The three-year underlying earnings growth at Anhui Anke Biotechnology (Group) (SZSE:300009) is promising, but the ... - Simply Wall St - March 28th, 2024
- Is Lyra Therapeutics Inc (LYRA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- Should You Sell 4D Molecular Therapeutics Inc (FDMT) in Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- SPMVV receives 47.9 lakh grant from the governments Department of Biotechnology - The Hindu - March 28th, 2024
- Where Does IGC Pharma Inc (IGC) Stock Fall in the Biotechnology Field After It Is Up 14.71% This Week? - InvestorsObserver - March 28th, 2024
- Report Lays Out Road Map to Transform Understanding of RNA and Invest in RNA Science and Biotechnology - National Academies of Sciences, Engineering,... - March 28th, 2024
- Is Akebia Therapeutics Inc (AKBA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2024
- Singapore and Indonesia to foster bilateralism in healthcare, digital health, and biotechnology - BSA bureau - March 28th, 2024
- Where Does Gossamer Bio Inc (GOSS) Stock Fall in the Biotechnology Field After It Is Lower By -14.07% This Week? - InvestorsObserver - March 28th, 2024
- Where Does Equillium Inc (EQ) Stock Fall in the Biotechnology Field After It Is Down -31.25% This Week? - InvestorsObserver - March 28th, 2024
- Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin - FDA.gov - January 14th, 2024
- An Introduction to Biotechnology - PMC - National Center for ... - January 14th, 2024
- Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Yahoo Finance - January 14th, 2024
- Digital Life Norway (DLN) Initiative to foster and boost transdisciplinary biotechnology research and innovation - Open Access Government - January 14th, 2024
- Is Elevation Oncology Inc (ELEV) a Bad Choice in Biotechnology Thursday? - InvestorsObserver - January 14th, 2024
- Is Cytokinetics, Inc. (CYTK) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Is Regeneron Pharmaceuticals Inc (REGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Is Axsome Therapeutics Inc (AXSM) a Good Buy in the Biotechnology Industry? - InvestorsObserver - January 14th, 2024
- Where Does Immunovant Inc (IMVT) Stock Fall in the Biotechnology Field After It Is Higher By 11.63% This Week? - InvestorsObserver - January 14th, 2024
- Should Biotechnology Stock Harpoon Therapeutics Inc (HARP) Be in Your Portfolio Wednesday? - InvestorsObserver - November 24th, 2023
- Should Biotechnology Stock SpringWorks Therapeutics Inc (SWTX) Be in Your Portfolio Wednesday? - InvestorsObserver - November 24th, 2023
- Where Does Cassava Sciences Inc (SAVA) Stock Fall in the Biotechnology Field After It Has Fallen -1.24% This Week? - InvestorsObserver - November 24th, 2023
- Where Does Kalvista Pharmaceuticals Inc (KALV) Stock Fall in the Biotechnology Field After It Is Lower By -1.04% This Week? - InvestorsObserver - November 24th, 2023
- Should Biotechnology Stock Theravance Biopharma Inc (TBPH) Be in Your Portfolio Thursday? - InvestorsObserver - April 23rd, 2023
- Where Will Sana Biotechnology Inc (SANA) Stock Go Next After It Is Down 1.35% in a Week? - InvestorsObserver - April 23rd, 2023
- Where Does Novo Nordisk A/S (NVO) Stock Fall in the Biotechnology Field After It Has Fallen -1.71% This Week? - InvestorsObserver - April 23rd, 2023
- Where Does Seagen Inc (SGEN) Stock Fall in the Biotechnology Field After It Is Lower By -0.81% This Week? - InvestorsObserver - April 23rd, 2023
- MSc Admissions at Institute of Bioinformatics and Applied Biotechnology, Bengaluru - Mathrubhumi English - April 23rd, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 28th, 2023
- Biotechnology - Applications of biotechnology | Britannica - March 28th, 2023
- Biotechnology | FAO | Food and Agriculture Organization of the United ... - March 28th, 2023
- What is Biotechnology? Types and Applications - Iberdrola - March 28th, 2023
- Should Biotechnology Stock Checkpoint Therapeutics Inc (CKPT) Be in Your Portfolio Monday? - InvestorsObserver - March 28th, 2023
- Where Does IGM Biosciences Inc (IGMS) Stock Fall in the Biotechnology Field After It Has Fallen -1.80% This Week? - InvestorsObserver - March 28th, 2023
- Is Day One Biopharmaceuticals Inc (DAWN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 28th, 2023
- Where Does Jasper Therapeutics Inc (JSPR) Stock Fall in the Biotechnology Field After It Has Risen 3.16% This Week? - InvestorsObserver - March 28th, 2023
- Is Evaxion Biotech A/S - ADR (EVAX) a Leader in the Biotechnology Industry? - InvestorsObserver - February 14th, 2023
- Where Does Oncolytics Biotech Inc (ONCY) Stock Fall in the Biotechnology Field After It Has Risen 1.72% This Week? - InvestorsObserver - February 14th, 2023
- Where Does Surrozen Inc (SRZN) Stock Fall in the Biotechnology Field After It Is Up 59.74% This Week? - InvestorsObserver - February 14th, 2023
- International Biotechnology Trust's Investment Manager to Focus on Core Healthcare Business - Marketscreener.com - February 14th, 2023
- Where Does Ocugen Inc (OCGN) Stock Fall in the Biotechnology Field After It Is Lower By -14.73% This Week? - InvestorsObserver - February 14th, 2023
- Is Protagonist Therapeutics Inc (PTGX) a Smart Choice in Biotechnology Friday? - InvestorsObserver - February 14th, 2023
- Where Does Kiora Pharmaceuticals Inc (KPRX) Stock Fall in the Biotechnology Field After It Has Risen 33.24% This Week? - InvestorsObserver - February 14th, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Up 0.46% This Week? - InvestorsObserver - February 14th, 2023
- City of Vacaville Introduces Next Generation to Biotechnology and Advanced Manufacturing - Financial Post - February 6th, 2023
- Is Incyte Corporation (INCY) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - February 6th, 2023
- Where Does Catalyst Pharmaceuticals Inc (CPRX) Stock Fall in the Biotechnology Field After It Is Down -3.88% This Week? - InvestorsObserver - February 6th, 2023
- Where Does Summit Therapeutics Inc (SMMT) Stock Fall in the Biotechnology Field After It Is Up 8.63% This Week? - InvestorsObserver - February 6th, 2023
- Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Down -2.89% This Week? - InvestorsObserver - February 6th, 2023
- Should You Be Impressed By Puma Biotechnology, Inc.'s (NASDAQ:PBYI) ROE? - Simply Wall St - January 21st, 2023
- Where Does Palisade Bio Inc (PALI) Stock Fall in the Biotechnology Field After It Is Lower By -11.27% This Week? - InvestorsObserver - January 21st, 2023
- Is Autolus Therapeutics PLC (AUTL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 21st, 2023
- Where Does Edesa Biotech Inc (EDSA) Stock Fall in the Biotechnology Field After It Has Fallen -39.16% This Week? - InvestorsObserver - January 21st, 2023
- Where Does Vaxcyte Inc (PCVX) Stock Fall in the Biotechnology Field After It Has Fallen -7.21% This Week? - InvestorsObserver - January 12th, 2023
- Where Does CytomX Therapeutics Inc (CTMX) Stock Fall in the Biotechnology Field After It Is Up 61.68% This Week? - InvestorsObserver - January 12th, 2023
- Where Does Vyant Bio Inc (VYNT) Stock Fall in the Biotechnology Field After It Is Up 36.36% This Week? - InvestorsObserver - January 12th, 2023
- Is CTI BioPharma Corp (CTIC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 12th, 2023
- Where Does Jaguar Health Inc (JAGX) Stock Fall in the Biotechnology Field After It Has Gained 22.22% This Week? - InvestorsObserver - January 12th, 2023
- Where Does Geron Corporation (GERN) Stock Fall in the Biotechnology Field After It Has Gained 9.09% This Week? - InvestorsObserver - January 12th, 2023
- Is OncoSec Medical Inc (ONCS) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 12th, 2023
- What is Biotechnology? Master of Biotechnology - January 4th, 2023
- Where Does Chemomab Therapeutics Ltd - ADR (CMMB) Stock Fall in the Biotechnology Field After It Has Gained 52.97% This Week? - InvestorsObserver - January 4th, 2023
- Should Biotechnology Stock Galera Therapeutics Inc (GRTX) Be in Your Portfolio Wednesday? - InvestorsObserver - January 4th, 2023
- Where Does 180 Life Sciences Corp (ATNF) Stock Fall in the Biotechnology Field After It Is Lower By -26.07% This Week? - InvestorsObserver - January 4th, 2023
- Is Adaptive Biotechnologies Corp (ADPT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Is ImmunoGen, Inc. (IMGN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Is DBV Technologies SA - ADR (DBVT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - January 4th, 2023
- Does PDS Biotechnology Corp (PDSB) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver - December 27th, 2022
- Where Does Intercept Pharmaceuticals Inc (ICPT) Stock Fall in the Biotechnology Field After It Is Lower By -10.50% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Merrimack Pharmaceuticals Inc (MACK) Stock Fall in the Biotechnology Field After It Has Fallen -10.39% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Compass Therapeutics Inc. (CMPX) Stock Fall in the Biotechnology Field After It Is Higher By 2.68% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Allogene Therapeutics Inc (ALLO) Stock Fall in the Biotechnology Field After It Is Lower By -19.38% This Week? - InvestorsObserver - December 27th, 2022
- Where Does Oramed Pharmaceuticals, Inc. (ORMP) Stock Fall in the Biotechnology Field After It Is Higher By 11.42% This Week? - InvestorsObserver - December 27th, 2022
- Is Calithera Biosciences Inc (CALA) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - December 27th, 2022